0001209191-20-060717.txt : 20201130
0001209191-20-060717.hdr.sgml : 20201130
20201130160018
ACCESSION NUMBER: 0001209191-20-060717
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201125
FILED AS OF DATE: 20201130
DATE AS OF CHANGE: 20201130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Munshi Amit
CENTRAL INDEX KEY: 0001612551
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31161
FILM NUMBER: 201358154
MAIL ADDRESS:
STREET 1: C/O EPIRUS BIOPHARMACEUTICALS, INC.
STREET 2: 699 BOYLSTON STREET, 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001080709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 232908305
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-453-7200
MAIL ADDRESS:
STREET 1: 6154 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-25
0
0001080709
ARENA PHARMACEUTICALS INC
ARNA
0001612551
Munshi Amit
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO
CA
92121
1
1
0
0
President and CEO
Common Stock
2020-11-25
4
M
0
11700
0.00
A
19450
D
Common Stock
2020-11-25
4
F
0
5183
65.50
D
14267
D
Performance Restricted Stock Unit
2020-11-25
4
M
0
11700
0.00
D
2022-01-03
Common Stock
11700
23400
D
On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement.
Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs.
The amount reported in Column 7 of Table II represents the common shares that vested on November 25, 2020. The PRSUs' final Closing Price target has been met and the Reporting Person has a contingent right to receive 23,400 additional common shares if the subsequent continuing service requirement is met.
/s/ Andrew J. Cronauer, as Attorney-in-Fact
2020-11-30